Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04483011Not ApplicableUnknown

The Safety and Efficacy Study of RiaGev in Healthy Adults

Role: lead

NCT01108549Not ApplicableCompleted

Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study

Role: collaborator

NCT00821067Not ApplicableCompleted

The Effect of Oral D-Ribose in "Baby Boomers" With Fatigue. A Randomized, Double-Blind Study

Role: lead

NCT00566514Not ApplicableSuspended

The Role of Ribose in Patients Diagnosed With Fibromyalgia

Role: lead

All 4 trials loaded